MD, Public Health Epidemiologist/ Head of Research


Dr. Asante holds a BSc. in Medical Sciences, MD degree, Masters in Public Health from University of Ghana; and a PhD in infectious disease epidemiology from the London School of Hygiene and Tropical Medicine, UK. Dr. Asante also hold several certificates of public health advocacy, advanced epidemiology, medical ethics and good clinical practices.

Dr. Asante provided primary health care in rural Ghana after his internship at Korle-Bu Teaching Hospital in Ghana. He has interest in epidemiology of childhood illnesses particularly malaria and respiratory infections, health programme evaluation and access to health care.

Dr. Asante has served on several international and local public health committees. He is currently the Chair of an expert oversight committee to evaluate the impact of clinical trials in Africa (eICT Study) and a Co-chair of the Clinical Trial Partnership for RTSS malaria clinical trials in Africa.

Dr. Asante was the Head of Malaria Research for 8 years at the Kintampo Health Research Centre (KHRC) and currently the Head of Research and a management committee member at KHRC.

Dr. Asante is a visiting lecturer at the School of Public Health in Ghana and the Columbia University Mailman School of Public Health in the U. S. A. and has supervised several student thesis.

Dr. Asante has papers in peer review journals and has authored a book chapter.

  • Malaria Vaccine Initiative, USA, Malaria Vaccine Trials, March 2006 – 2009
  • GlaxoSmithkline,UK Clorproguanil-dapsone drug trial, June 2006 – June 2007
  • Newmont Ghana Gold Ltd, Baseline Health Survey in Asutifi, Tano and Techiman Districts of Ghana, June 2006 – June 2008
  • Ghanaian Dutch Collaboration for Health Research, Compliance to artesunate-amodiaquine study. Oct. 2005 – Oct. 2006
  • Ghana National Malaria Control Programme/ Global Fund, Assessment of community knowledge, attitudes and perception of Artesunate-amodiaquine, Nov. 2005
  • Research Experience:

    Co-Principal Investigator: A Phase two multi-centre trials of GSK’s RTSS,S vaccine involving 440 children, March 2006 – June 2008.

    Principal Investigator: Compliance to artesunate-amodiaquine, a pragmatic study Oct. 2005 – Oct. 2006. This study sought to assess patient’s compliance to artesuante amodiaquine to guide policy in educational messages to ensure compliance and prevent drug resistance.

    Principal Investigator: Knowledge, attitudes, perceptions and reactions to artesunate-amodiaquine 2005 – Nov. 2006. The aim of this study was to explore the communities knowledge, attitudes and perceptions to the new antimalarial drug artesuante –amodiaquine. This study was essential in light of the public’s outcry with the introduction of artesuante amodiaquine for the treatment of uncomplicated malaria.

    Principal Investigator: Baseline Health Survey in the Asutifi, Tano N/S districts using techiman as a control area. The aim of this study was to determine baseline health indices that would be used in monitoring and evaluating public health interventions in a mining area.

    Co-Investigator: Prevalence of G6PD diffeciency among pregnant women in Ghana and reactions to Sulphurdoxine-Pyrimethamine (SP). The aim of this study was to determine the prevalence of G6PD deficiency among pregnant women and the burden of reactions when they routinely receive SP at the antenatal clinics.

    Project Coordinator –MeVISS project (July 2004 – Nov. 2005): There was a fatal outbreak of W135 strain of N. meningococci in 2002 in Burkina Faso. This study evaluated the immunogenicity and safety of a cheaper GSK Nm ACW135 polysaccharide vaccine with an expensive Nm ACYW135 polysaccharide vaccine. This study is in collaboration with the Navrongo Health Research Center, Ghana Health Service and the London School of Hygiene and Tropical Medicine.

    Co-Investigator, Gates Malaria Partnership Project 1 (October 2003 - November 2004) : The general objective of this study was to determine baseline indices of malaria in the Kintampo district as a site for future malaria drug and vaccine studies. This study is in collaboration with the Noguchi Medical Research Institute, University of Ghana, Ghana and the London School of Hygiene and Tropical Medicine.

    Co-Investigator, Gates Malaria Partnership Project 2: The main aim of this study was to evaluate the efficacy of artemisinin combination drugs for treating uncomplicated falciparum malaria in the study area. The profiles of these drugs will help in choosing an efficacious drug for intermittent preventive treatment in infant/children.

    Co-Investigator –Sprinkles project (March 2002 – 2006): The Sprinkles projects were a series of studies that sought to determine the efficacy, acceptability, and effectiveness of sprinkles (powdered microencapsulated iron) to address the burden of nutritional anemia. These have been in collaboration with the Hospital for Sick-kids, Canada. Policy implications are being considered.

    Project Clinician –EPI ++ study (September 2002 – October 2004): The objective of this study was to evaluate the WHO newly proposed mode of supplementation of young infants and their mothers with Vitamin A.

    Dr. Asante is a member of the following professional associations:
    Member, Ghana Medical Association
    Member, Association of Clinical Research Professionals, East African Chapter
    Member, Newmont Gold Mining Committee on Community Health & Social Welfare Committee.


    1. Cairns ME, Asante KP, Owusu-Agyei S, Chandramohan D., Greenwood B, Milligan PJ, Analysis of partial and complete protection in malaria cohort studies. Accepted at Malaria Journal, Sep. 2013
    2. Asante KP , Tawiah-Agyeman C, Zandoh C, Saah, J, Febir, LG, Donlebo CK, Owusu-Agyei S. Community engagement in biomedical research in an African setting: the Kintampo Health Research Centre experience. Accepted at BMC Health Services Research, Sep. 2013
    3. Asante KP , Owusu-Agyei S , Cairns M , Dodoo D , Boamah EA , Gyasi R , Adjei G , Gyan B , Agyeman-Budu A , Dodoo T , Mahama E , Amoako N , Dosoo DK , Koram K , Greenwood B , Chandramohan D . Placental malaria and the risk of malaria in infants in a high malaria transmission area in Ghana: a prospective cohort study. J Infect Dis. 2013 Aug 1
    4. Febir LG, Asante KP, Dzorgbo DB, Senah KA, Letsa TS, Owusu-Agyei S. Community perceptions of a malaria vaccine in the Kintampo districts of Ghana. Malar J. 2013 May 7;12:156. doi: 10.1186/1475-2875-12-156.
    5. Bejon P, White MT, Olotu A, Bojang K, Lusingu JP, Salim N, Otsyula NN, Agnandji ST, Asante KP, Owusu-Agyei S, Abdulla S, Ghani AC. Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data. Lancet Infect Dis. 2013 Apr;13(4):319-27. doi: 10.1016/S1473-3099(13)70005-7. Epub 2013 Mar 1.
    6. Osei-Kwakye K , Asante KP , Mahama E , Apanga S , Owusu R , Kwara E , Adjei G , Abokyi L , Yeetey E , Dosoo DK , Punguyire D , Owusu-Agyei S . The benefits or otherwise of managing malaria cases with or without laboratory diagnosis: the experience in a district hospital in Ghana. PLoS One. 2013;8(3):e58107. . Epub 2013 Mar 7
    7. Agyeman-Budu A, Brown C, Adjei G, Adams M, Dosoo D, Dery D, Wilson M, Asante KP, Greenwood B, Owusu-Agyei S. Trends in multiplicity of Plasmodium falciparum infections among asymptomatic residents in the middle belt of Ghana. Malar J. 2013 Jan 17;12:22. doi: 10.1186/1475-2875-12-22.
    8. RTS,S Clinical Trials Partnership, et al A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med. 2012 Dec 13;367(24):2284-95. doi: 10.1056/NEJMoa1208394. Epub 2012 Nov 9.**
    9. Adu-Gyasi D, Adams M, Amoako S, Mahama E, Nsoh M, Amenga-Etego S, Baiden F, Asante KP, Newton S, Owusu-Agyei S. Estimating malaria parasite density: assumed white blood cell count of 10,000/μl of blood is appropriate measure in Central Ghana. Malar J. 2012 Jul 23;11:238. doi: 10.1186/1475-2875-11-238.
    10. Dosoo DK, Kayan K, Adu-Gyasi D, Kwara E, Ocran J, Osei-Kwakye K, Mahama E, Amenga-Etego S, Bilson P, Asante KP, Koram KA, Owusu-Agyei S. Haematological and biochemical reference values for healthy adults in the middle belt of Ghana. PLoS One. 2012;7(4):e36308. Epub 2012 Apr 27.
    11. RTS,S Clinical Trials Partnership, et al First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med. 2011 Nov 17;365(20):1863-75. Epub 2011**
    12. Asante KP , Zandoh C, Dery DB, Brown C, Adjei G, Antwi-Dadzie Y, Adjuik M, Tchum K, Dosoo D, Amenga-Etego S, Mensah C, Owusu-Sekyere KB, Anderson C, Krieger G, Owusu-Agyei S. Malaria epidemiology in the Ahafo area of Ghana. Malar J. 2011 Jul 29;10:211.
    13. Asante KP , Abdulla S, Agnandji S, Lyimo J et al. RTS,S/AS01E malaria candidate vaccine delivered with vaccines from the Expanded Program of Immunization: 19 months evaluation shows favourable safety and prevention of malaria above 50% Lancet Infect Dis. 2011 Oct;11(10):741-9
    14. Vekemans J, Marsh K, Greenwood B, Leach A, Kabore W, Soulanoudjingar S, Asante KP, Ansong D, Evans J, Sacarlal J, Bejon P, Kamthunzi P, Salim N, Njuguna P, Hamel MJ, Otieno W, Gesase S, Schellenberg D; Clinical Trials Partnership Committee. Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care. Malar J. 2011 Aug 4;10:221.
    15. Swysen C, Vekemans J, Bruls M, Oyakhirome S, Drakeley C, Kremsner P, Greenwood B, Ofori-Anyinam O, Okech B, Villafana T, Carter T, Savarese B, Duse A, Reijman A, Ingram C, Frean J, Ogutu B; Clinical Trials Partnership Committee. Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine. Malar J. 2011 Aug 4;10:223
    16. Ansong D, Asante KP, Vekemans J, Owusu SK, Owusu R, Brobby NA, Dosoo D, Osei-Akoto A, Osei-Kwakye K, Asafo-Adjei E, Boahen KO, Sylverken J, Adjei G, Sambian D, Apanga S, Kayan K, et. al. T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children. PLoS One. 2011 Apr 27;6(4):e18891.
    17. Agnandji ST, Asante KP, Lyimo J, Vekemans J, Soulanoudjingar SS, Owusu R, Shomari M, Leach A, Fernandes J, Dosoo D, Chikawe M, Issifou S, Osei-Kwakye K, Lievens M, Paricek M, Apanga S, et. al. Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J Infect Dis. 2010 Oct 1;202(7):1076-87
    18. Dery DB, Brown C, Asante KP, Adams M, Dosoo D, Amenga-Etego S, Wilson M, Chandramohan D, Greenwood B, Owusu-Agyei S. Patterns and seasonality of malaria transmission in the forest-savannah transitional zones of Ghana. Malar J. 2010 Nov 7;9 (1):314
    19. Asante KP , Abokyi L. Zandoh C, Owusu R, Awini E, Abubakari S, Amenga-Etego S, Adda R, Boahen O, Segbaya S, Mahama E, Bart-Plange C, Chandramohan D, Owusu-Agyei S. Community perceptions of malaria and malaria treatment behaviour in a rural district of Ghana: implications for artemisinin combination therapy. BMC Public Health 2010, 10:409
    20. Asante KP , Owusu R, Dosoo D, Awini E, Adjei G, Amenga Etego S, Chandramohan D, Owusu-Agyei S. Adherence to Artesunate-Amodiaquine Therapy for UncomplicatedMalaria in Rural Ghana: A Randomised Trial of Supervised versus Unsupervised Drug Administration. J Trop Med. 2009; 2009:529583
    21. Newton S, Doku V, Geissler W, Asante KP, Cousens S. Drawing blood from young children: lessons learned from a trial in Ghana. Trans R Soc Trop Med Hyg. 2009 May;103(5):497-9.
    22. Seth Owusu-Agyei D. Ansong, Asante KP, S. Owusu-Kwarteng, et al Evaluation of RTS,S/AS02D and RTS,S/AS01E Malaria Candidate Vaccines when given according to different Vaccination Schedules in Ghanaian Children PLoS One. 2009 Oct 2;4(10):e7302
    23. Owusu-Agyei S, Asante KP, Owusu R, Adjuik M, Amenga-Etego S, Dosoo DK, Gyapong J, Greenwood B, Chandramohan D 2008) An Open Label, Randomised Trial of Artesunate+Amodiaquine, Artesunate+Chlorproguanil-Dapsone and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria. PLoS ONE 3(6): e2530. doi:10.1371/ journal.pone.0002530
    24. Chandramohan D , Hodgson A , Coleman P , Baiden R , Asante K P , Awine E , Owusu-Agyei S , Boutriau D , Nelson CB , Greenwood B .An evaluation of the immunogenicity and safety of a new trivalent meningococcal polysaccharide vaccine Vaccine. Vaccine. 2007 Sep 3;25 Suppl 1:A83-91. Epub 2007 May 7
    25. Moorthy V, Reed Z, Smith PG; WHO Study Group on Measures of Malaria Vaccine Efficacy. Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation. Vaccine. 2007 Jul 9;25(28):5115-23.
    26. Christofides A , Asante KP , Schauer C , Sharieff W , Owusu-Agyei S , Zlotkin S . Multi-micronutrient Sprinkles including a low dose of iron provided as microencapsulated ferrous fumarate improves haematologic indices in anaemic children: a randomized clinical trial. Matern Child Nutr. 2006 Jul;2(3):169-80.
    27. Zlotkin SH, Schauer C, Owusu Agyei S, Wolfson J, Tondeur MC, Asante KP, Newton S, Serfass RE, Sharieff W. Demonstrating zinc and iron bioavailability from intrinsically labeled microencapsulated ferrous fumarate and zinc gluconate Sprinkles in young children.
      J Nutr. 2006 Apr; 136(4):920-5.
    28. Tondeur MC, Schauer CS, Christofides AL, Asante KP, Newton S, Serfass RE, Zlotkin SH. Determination of iron absorption from intrinsically labeled microencapsulated ferrous fumarate (sprinkles) in infants with different iron and hematologic status by using a dual-stable-isotope method. Am J Clin Nutr. 2004 Nov;80(5):1436-44.

    Book/ Newsletter Contributions

    1. Asante K. P. Idindili B, Adedapo, A. D. A, Kayange N. Report on AMANET workshop on proposing and reporting on intervention trials for African Researchers. Newsletter of the African Malaria Network Trust. Newsletter of the African Malaria Network Trust. ISSN 0856 7646 No. 16 December, 2004 No. 16 December, 2004
    2. Asante K. P. Owusu-Agyei S. Health Impact Assessment in Ghana. Kemm J. Health Impact Assessment Oxford University Press. 2012